United States Patent 7,981,439: Scope, Claim Metrics, and U.S. Patent Landscape for Polyethylene Oxide Abuse-Deterrent Formulations

US Drug Patent 7,981,439 covers a specific abuse-deterrent therapeutic composition built around a water-soluble abuse-susceptible drug, polyethylene oxide (PEO) 3%–40% by weight, a specific superdisintegrant class at 2%–25%, and sodium lauryl sulfate (SLS) 1%–10%, with optional inclusion of an emetic (zinc sulfate). The estate scope is medium-narrow on formulation ingredients and ranges, but broad on drug identity (“a water soluble drug susceptible to abuse”), and broad on dosage forms.

What does US Patent 7,981,439 claim cover: scope, ingredient limits, and dosage-form reach?

Core claim coverage (claim 1) is a composition of four defined elements plus optional extensions:

A water soluble drug susceptible to abuse
PEO at about 3% to about 40% by weight
Disintegrant at about 2% to 25% by weight, selected from:
- crospovidone
- sodium starch glycolate
- croscarmellose sodium
Sodium lauryl sulfate at about 1% to 10% by weight

Claim scope is anchored by ranges and ingredient identity. A product outside any of these numeric windows, or using a different disintegrant not in the enumerated list, falls outside claim 1 (absent doctrine-of-equivalents arguments). Conversely, any abuse-deterrent product meeting all four ingredient/range limitations is within claim 1 regardless of the specific abuse-deterrable drug, as long as it fits the claim’s “water soluble drug susceptible to abuse” characterization.

How broad is the “water soluble drug susceptible to abuse” element?

Claim 1 does not name a drug. It reads on an ingredient class: water-soluble substances that are susceptible to abuse. That phrase creates argument-driven coverage rather than hard enumerations.

Practically, this tends to sweep in reformulations for commonly abused, water-soluble small molecules (and possibly other therapeutics if they can be framed as “susceptible to abuse”). From a patent-landscape view, this broad drug element increases infringement surface area across different NDA/ANDA assets, provided the formulation matches the polymer-surfactant-disintegrant architecture.

What exactly is protected by the PEO requirement?

PEO is set as a key excipient at 3%–40% w/w. PEO is widely used in controlled release and tablet wetting/gel-layering contexts. The claim narrows the protection by requiring a combination of PEO plus:

enumerated disintegrant type,
SLS,
and water-soluble abuse-prone drug.

What does the disintegrant restriction do to infringement risk?

The disintegrant is limited to one of three superdisintegrants at 2%–25% w/w:

crospovidone
sodium starch glycolate
croscarmellose sodium

This is a relatively tight formulation gate. Many abuse-deterrent formulations use other disintegrants (e.g., L-HPC, SCMC, starch, polyplasdone types not within the listed name set, microcrystalline cellulose binders, or other superdisintegrants). Using non-listed disintegrants is a direct design-around in claim 1.

How critical is sodium lauryl sulfate (SLS)?

SLS is required at 1%–10% w/w. That creates another high-value infringement lever because SLS is a common surfactant/wetting agent, but many abuse-deterrent products use alternative surfactants (e.g., polysorbates, sodium stearyl fumarate, triethyl citrate as a processing aid, etc.). Claim coverage is contingent on SLS presence and within range.

Dosage forms: how far does claim 6 reach?

Claim 6 includes broad unit-type and physical formats:

suppository
capsule
caplet
pill
gel
soft gelatin capsule
compressed tablet

This is expansive coverage across solid and semi-solid oral formats plus suppositories. If a competitor restricts to e.g. only immediate-release tablets with specific coatings, the presence of claim 6 still captures “compressed tablet form” but may not cover an intranasal or transdermal format.

How do claims 2 and 3 expand coverage: what about emetics and zinc sulfate?

Claim 2 adds: the composition of claim 1 further comprises an emetic.

Claim 3 narrows: the emetic is zinc sulfate.

This creates a layered structure:

If an accused product has the base composition of claim 1, it can still fall outside claims 2–3 if it contains no emetic, or uses a different emetic.
If zinc sulfate is used as the emetic, exposure increases by meeting claim 3.

From a landscape standpoint, most abuse-deterrent formulations include aversion elements via emetics or antagonist components, but zinc sulfate specifically may be less common than alternatives. Where zinc sulfate is present for aversion, this patent becomes a stronger obstacle.

What claim 4 adds: molecular weight scope for polyethylene oxide?

Claim 4 specifies PEO molecular weight: 300,000 to about 5,000,000.

This is an important tightening relative to claim 1’s concentration window. Even if a competitor uses PEO within 3%–40% but uses a PEO outside that molecular-weight band, claim 1 could still be implicated if claim 4 is not required. In claim dependency terms:

Claim 4 depends on claim 1, so claim 4 coverage requires satisfying claim 1 plus the molecular weight range.
Many litigation theories use claim 1 first; claim 4 acts as a secondary, more restrictive hook.

In practice, PEO molecular weight selection affects viscosities, gel formation kinetics, and potentially abuse deterrence performance. This molecular weight boundary therefore matters for both infringement analysis and engineering design-arounds.

What claims 5–7 cover: unit dose and water-soluble drug loading?

Claim 5: unit dose form.
Claim 6: lists dosage formats (already covered above).
Claim 7: water soluble drug present at 0.5% to about 25% by weight.

Claim 7 is additional narrowing. A formulation using a higher drug loading above 25% might still potentially satisfy claim 1 but could fail claim 7 if claim 7 is asserted as the basis. For portfolio and litigation exposure assessment, drug loading is a key numeric design lever.

How many distinct formulation “design dimensions” are required to infringe claim 1?

Claim 1 requires satisfaction of all four dimensions:

Drug attribute: water soluble abuse-susceptible drug (not a named list)
PEO: 3%–40%
Disintegrant identity and level: one of three enumerated superdisintegrants at 2%–25%
SLS: 1%–10%

A competitor can attempt a design-around by changing any one dimension:

exclude SLS or shift outside 1%–10%
swap disintegrant to a non-enumerated disintegrant
shift PEO concentration outside 3%–40%
use a drug not plausibly framed as “water soluble drug susceptible to abuse” (still argument-dependent)
move drug level outside 0.5%–25% if claim 7 is asserted

What is the likely “claim construction” pressure points for litigation on this patent?

The pressure points typically cluster into:

1) “water soluble drug susceptible to abuse”

This is a functional/characterization element. Evidence in litigation tends to rely on:

solubility in relevant media,
regulatory history and misuse patterns,
labeling and enforcement background,
and formulation intent to deter abuse.

Because the claim is not limited to specific drugs, this term becomes a central factual/legal issue.

2) “selected from the group consisting of” for disintegrants

This is a “closed” list in patent claim language. If a product uses a disintegrant not named in the list, it is not within the “selected from” requirement (unless equivalence is argued, which is hard to win with a closed transition).

3) Percent-by-weight ranges “about”

The use of “about” creates tolerance. Still, numeric ranges remain measurable. Claim 1’s critical ranges can be converted into “likely infringing” bands depending on established acceptable deviation practices in the relevant case law.

4) Dosage forms

Claim 6 gives explicit enumerations. A product in a different administration format avoids direct match, but doctrine-of-equivalents could be argued if the format performs similarly.

Patent landscape: what other U.S. patents likely co-exist around abuse-deterrent PEO + disintegrant + surfactant compositions?

A complete, database-verified landscape cannot be generated from the claim text alone because it requires:

the patent’s bibliographic record (assignee, filing dates),
citation graph (forward and backward references),
and family members and continuation/divisional status.

Because no bibliographic record is provided here, the landscape below focuses on what the claims imply about the surrounding technology space and how it typically clusters in patent portfolios.

Adjacent technology clusters (expected in co-cited portfolios)

This patent’s formulation architecture is consistent with several common abuse-deterrent excipient strategies:

Polymer-based gelation or barrier formation (PEO is often associated with hydrophilic gel layers)
Wetting/surfacing control using surfactants like SLS
Fast disintegration control for normal use using superdisintegrants (crospovidone, sodium starch glycolate, croscarmellose sodium)

These excipient families usually appear in patent portfolios that cover:

abuse-deterrent immediate release tablets,
anti-tamper formulations,
and aversion/repellent components (where zinc sulfate or other aversives are included)

How to map likely competing claim territories

Competitors typically try to avoid patents like this by one of three routes:

Change disintegrant chemistry
- Using disintegrants not in the closed list
Replace surfactant
- Dropping SLS or substituting different surfactants
Adjust polymer
- Changing PEO concentration or using a different polymer system (e.g., HPMC, ethylcellulose blends, PEO-poloxamers, crosslinked polymers)
- Or selecting different PEO molecular weights, attacking claim 4 exposure

How does US 7,981,439 compare with typical abuse-deterrent patent “claim patterns”?

This patent is excipient-defined rather than drug-defined

Many abuse-deterrent patents are tied to a named API or to a specific antagonist/aversion molecule. Here, the API is not named, which can increase portfolio value across multiple APIs if the formulation is transferable.

It has hard numeric gates

PEO (3%–40%), disintegrant (2%–25%), SLS (1%–10%), drug loading (0.5%–25%) create straightforward infringement checks when formulations are disclosed through labels, patents, ANDA exhibits, or discovery.

Dosage forms are broad

Claim 6 covers multiple unit dose formats, reducing format-specific escape routes.

Orange Book and Paragraph IV/ANDA risk: what does this claim imply for generic entry scenarios?

A full Orange Book status assessment requires the drug names and the Orange Book database listings; those inputs are not provided. However, conceptually:

If a generic seeks to market an abuse-deterrent equivalent with the same formulation architecture, it faces composition infringement risk under claim 1.
If the branded product’s patent strategy includes 7,981,439 in Orange Book listings for a relevant NDA, ANDA applicants must address it via:
- non-infringement/invalidity arguments,
- or a Paragraph IV certification with litigation/settlement.

The specific numeric and ingredient identity requirements are helpful for ANDA design-arounds:

change disintegrant identity
remove SLS
move polymer concentration
adjust drug loading

Which elements most likely drive validity challenges or design-around success?

Validity attack vectors (conceptual)

Without prosecution history or citations, only generic pathways can be stated from claim structure:

Anticipation/obviousness based on prior art abuse-deterrent excipient systems combining PEO, superdisintegrants, and surfactants.
Obviousness if each ingredient/range was known for abuse deterrence or for controlling disintegration plus wetting, and the combination yields predictable results.
Indefiniteness arguments are less likely because the ranges and ingredient identities are concrete; characterization terms (“water soluble drug susceptible to abuse”) may still become a focus.

Design-around vectors

Most direct:

replace the disintegrant with a non-enumerated one
replace SLS with another surfactant or eliminate it
use PEO concentration outside 3%–40%
use PEO molecular weight outside 300,000 to 5,000,000 (for claim 4)
change drug loading outside 0.5%–25% (for claim 7)
remove zinc sulfate if relying on claim 3

What business conclusions can be drawn from claim structure alone?

Claim 1 creates cross-API risk if multiple water-soluble abuse-prone APIs can be reformulated into the same excipient system. The patent is not limited by API identity.
Infringement is excipient-specific. Ingredient substitution (especially disintegrant identity and SLS presence) can be an effective route to non-infringement.
Zinc sulfate aversion is a stronger hook than generic “emetic” language because claim 3 nails an explicit chemical. Products using a different aversive may avoid claims 2–3.
Numeric range adherence is decisive. Pipelines and reformulation teams should treat PEO, disintegrant, SLS, and drug loading as litigation-critical parameters.

Key claim-to-exposure matrix

Claim	Additional limitation vs. claim 1	Litigation exposure driver
1	Base composition: abuse-susceptible water-soluble drug + PEO 3%–40% + (crospovidone or sodium starch glycolate or croscarmellose sodium) 2%–25% + SLS 1%–10%	Main infringement check
2	Further comprises an emetic	Aversion element required
3	Emetic is zinc sulfate	Highly specific; can be designed around by choosing different emetic or removing it
4	PEO MW 300,000 to 5,000,000	Tightens polymer grade requirement
5	Unit dose form	Impacts format, usually broad in practice
6	Dosage form includes suppository/capsule/caplet/pill/gel/soft capsule/compressed tablet	Format escape route exists if not one of these
7	Drug loading 0.5%–25% w/w	Drug dose formulation must match loading constraints

Key Takeaways

US 7,981,439 is a composition patent defined by PEO + enumerated superdisintegrants + SLS plus an abuse-susceptible water-soluble drug.
Claim 1 is medium-narrow on excipients (closed disintegrant list; SLS present within a defined band) but broad on API identity (no named drug).
Zinc sulfate is a high-specificity aversion element for claims 2–3, creating an identifiable design-around lever for aversion strategy.
Numeric range compliance is the fastest infringement screen: PEO (3%–40%), disintegrant (2%–25%), SLS (1%–10%), drug loading (0.5%–25%), and PEO molecular weight for claim 4.

FAQs

1) What formulation changes avoid US 7,981,439 claim 1 non-infringement?
Removing SLS (or shifting outside 1%–10%) and/or using a disintegrant outside crospovidone, sodium starch glycolate, and croscarmellose sodium materially reduces claim 1 coverage.

2) Does US 7,981,439 cover abuse-deterrent formulations without zinc sulfate?
Yes for claim 1 if all base excipient/range requirements are met; no for claims 2–3 unless an emetic is present and, for claim 3, it is zinc sulfate.

3) Is PEO molecular weight required for all of the patent’s claims?
No. PEO molecular weight (300,000 to 5,000,000) is a limitation of claim 4, not claim 1.

4) What dosage forms are explicitly listed in US 7,981,439?
Suppository, capsule, caplet, pill, gel, soft gelatin capsule, and compressed tablet.

5) How does drug loading affect claim coverage in US 7,981,439?
Claim 7 requires the water-soluble abuse-susceptible drug to be present at 0.5% to about 25% by weight; claim 1 does not include that loading limitation.

References (APA)

United States Patent and Trademark Office. US Patent 7,981,439 (claims provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004294953	⤷ Start Trial
Australia	2010200979	⤷ Start Trial
Australia	2013206525	⤷ Start Trial
Australia	2015264950	⤷ Start Trial
Australia	2017239544	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,981,439

Summary for Patent: 7,981,439